Entity

Time filter

Source Type

Cambridge, MA, United States

You M.-L.,Chienkuo Technical University | Wen K.-L.,Chienkuo Technical University | Liu K.-F.,GSK Company
Proceedings - 2011 International Conference on Future Computer Sciences and Application, ICFCSA 2011 | Year: 2011

As for the analysis of reliability and validity, they are applied to screen the questions of the questionnaire and determine the suitability of the questions, especially in the educational field. However, the results obtained from the questionnaire still cannot reach a decision. Hence, the paper provides the method of entropy, which uses randomness as the starting point, to quantify the uncertain problems and to offer auxiliary analysis of the results. Also, the method of entropy can make more complete results. First, the mathematics model of entropy is introduced in the paper followed by two examples. The reasonableness of the results of the questionnaire will be based on analyzing the factors' weighting. Besides, the Matlab GUI is used as the auxiliary tool to calculate the huge data. As the results, the method which proposed in this paper not only can verify the advantage of entropy, but also to achieve the integrity of complete educational questionnaire. © 2011 IEEE. Source


Dhawan S.S.,Center for Dermatology Clinical Research Inc | Dhawan S.S.,Stanford University | Gwazdauskas J.,GSK Company
Cutis | Year: 2013

Acne is a multifactorial chronic dermatosis that can be effectively treated with adjuvant medications. The objective of our study was to compare the tolerability and efficacy of 2 adjuvant therapies combining clindamycin phosphate 1.2%-benzoyl peroxide 5% (CLNP-BPO5) or clindamycin phosphate 1.2%-benzoyl peroxide 2.5% (CLNPBPO2.5) fixed-dose gels with tazarotene (TZ) cream 0.1% (CLNP-BPO5/TZ vs CLNP-BPO2.5/TZ) when applied topically once daily for 12 weeks in participants with moderate to severe facial acne. Forty participants were randomized to receive CLNP-BPO5/TZ or CLNP-BPO2.5/TZ in a parallel-group study and were evaluated at baseline as well as weeks 1, 2, 4, 8, and 12 (or at early termination). In both groups, tolerability assessments increased by week 1 but gradually returned toward baseline levels by week 12. At week 4, the mean change in burning/stinging was significantly higher in the CLNP-BPO5/TZ group compared with the CLNP-BPO2.5/TZ group (P<.05). No other significant differences were observed for the tolerability, efficacy, quality of life (QOL), or participant preference assessments. Our study shows that CLNP-BPO5 or CLNP-BPO2.5 fixed-dose gels in combination with TZ cream 0.1% are generally well-tolerated and effective treatments of moderate to severe facial acne when applied once daily for up to 12 weeks. Copyright Cutis 2013. Source


Cook D.,Concord Hospital | Krassas G.,Scius Solutions Pty Ltd | Huang T.,GSK Company
Australian Family Physician | Year: 2010

Background: Acne vulgaris can have a substantial impact on a patient's quality of life; there can be significant psychosocial consequences and it can leave permanent physical scarring. Early and effective acne treatment is important. Objective: To describe the outcome of an accredited clinical audit investigating general practitioner management of acne vulgaris and to provide an outline of current 'best practice' acne management. Discussion: The audit was conducted over two cycles with GPs receiving educational material between cycles. Eighty-five GPs contributed data on 1638 patients. General practitioner management of acne was assessed against a set of preset standards and some acne treatment was found to be inconsistent with best practice, particularly for patients with moderate and moderate to severe acne, where many patients were either being undertreated or treatment with antibiotic therapy was suboptimal. It is likely that this treatment gap is overestimated due to practical limitations of the audit process; however, the audit revealed a need to address the main sources of apparent divergence from best practice to improve the quality use of acne therapies. Source


Shindler K.S.,University of Pennsylvania | Ventura E.,Thomas Jefferson University | Dutt M.,University of Pennsylvania | Elliott P.,GSK Company | And 2 more authors.
Journal of Neuro-Ophthalmology | Year: 2010

Background: Neuronal loss in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), correlates with permanent neurological dysfunction. Current MS therapies have limited the ability to prevent neuronal damage. Methods: We examined whether oral therapy with SRT501, a pharmaceutical grade formulation of resveratrol, reduces neuronal loss during relapsing-remitting EAE. Resveratrol activates SIRT1, an NAD-dependent deacetylase that promotes mitochondrial function. Results: Oral SRT501 prevented neuronal loss during optic neuritis, an inflammatory optic nerve lesion in MS and EAE. SRT501 also suppressed neurological dysfunction during EAE remission, and spinal cords from SRT501-treated mice had significantly higher axonal density than vehicle-treated mice. Similar neuroprotection was mediated by SRT1720, another SIRT1-activating compound; and sirtinol, an SIRT1 inhibitor, attenuated SRT501 neuroprotective effects. SIRT1 activators did not prevent inflammation. Conclusions: These studies demonstrate that SRT501 attenuates neuronal damage and neurological dysfunction in EAE by a mechanism involving SIRT1 activation. SIRT1 activators are a potential oral therapy in MS. © 2010 by North American Neuro-Ophthalmology Society. Source


Kim S.J.,Ajou University | Kim C.S.,Asan Medical Center | Lee K.S.,Samsung | Jung J.I.,Busan Paik Hospital | And 2 more authors.
Yonsei Medical Journal | Year: 2012

Purpose: There are still debates on the benefit of mass screening for prostate cancer (PCA) by prostate specific antigen (PSA) testing, and on systemized surveillance protocols according to PSA level. Furthermore, there is a paucity of literature on current practice patterns according to PSA level in the Korean urologic field. Here, we report the results of a nationwide, multicenter, retrospective chart-review study. Materials and Methods: Overall 2122 Korean men (>40 years old, PSA >2.5 ng/mL) were included in our study (from 122 centers, in 2008). The primary endpoint was to analyze the rate of prostate biopsy according to PSA level. Secondary aims were to analyze the detection rate of PCA, the clinical features of patients, and the status of surveillance for PCA according to PSA level. Results: The rate of prostate biopsy was 7.1%, 26.3%, 54.2%, and 64.3% according to PSA levels of 2.5-3.0, 3.0-4.0, 4.0-10.0, and >10.0 ng/mL, respectively, and the PCA detection rate was 16.0%, 22.2%, 20.2%, and 59.6%, respectively. At a PSA level >4.0 ng/mL, we found a lower incidence of prostate biopsy in local clinics than in general hospitals (21.6% vs. 66.2%, respectively). A significant proportion (16.6%) of patients exhibited high Gleason scores (≥8) even in the group with low PSA values (2.5-4.0 ng/mL). Conclusion: We believe that the results from this nationwide study might provide an important database for the establishment of practical guidelines for the screening and management of PCA in Korean populations. © Yonsei University College of Medicine 2012. Source

Discover hidden collaborations